Liraglutide therapy in Type 1 Diabetes aims to decrease fasting and postprandial glucose concentrations

Type 1 diabetes (T1D) is an autoimmune condition marked by the destruction of pancreatic beta-cells, leading to absolute insulin deficiency. Despite advancements in insulin therapy, patients frequently contend with significant glycemic variability, the risk of hypoglycemia, and long-term complications. GLP-1 receptor agonists, such as liraglutide, have proven highly effective in Type 2 diabetes by enhancing glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. However, their precise role in T1D, where endogenous insulin production is minimal or absent, remains an active area of investigation, with research exploring potential benefits beyond insulin secretion, such as improved glycemic stability and reduced insulin requirements.

The provided context refers to a completed Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Trial (NCT01879917) designed to investigate liraglutide treatment in subjects with newly diagnosed Type 1 diabetes. The primary hypothesis guiding this study was that Liraglutide therapy would lead to a decrease in fasting, postprandial, and overall mean glucose concentrations. The trial's specific aims included comparing the mean fasting glucose, mean weekly glucose, and the standard deviation of weekly blood glucose concentrations between treatment and control arms. This trial, sponsored by Hvidovre University Hospital, completed in August 2018.

The provided text outlines the hypothesis and aims of a study investigating liraglutide in type 1 diabetes, but does not present any actual findings or results. Specifically, the core hypothesis was that Liraglutide treatment would decrease fasting, postprandial, and overall mean glucose concentrations in patients with Type 1 diabetes. The study's aim was to compare these glucose metrics, along with the standard deviation of weekly blood glucose concentrations. Without an abstract containing results, no specific numbers, p-values, or fold-changes can be reported. Therefore, this section cannot fulfill the character or content requirements for reporting findings, as no data is available to cite.